Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Bio Plexus, Inc. BPLX -- Ignore unavailable to you. Want to Upgrade?

To: cybstock who wrote (1)	6/4/1998 8:49:00 PM
From: Dennis	Read Replies (1) \| Respond to of 25

Hey cybstock, just started to do my homework on this company. My wife said the hospital she is at just started using their product. People in charge say it is a great product and are willing to spend the extra money because it will save them potential litigation, etc. Is it time to get this thread going or what?? I read the yahoo thread, I guess this company has its problems. They are not that far from where I live , maybe I will visit them and see what gives. Looks like OSHA and Congress may get into the act.

To: cybstock who wrote (1)	7/20/1998 9:54:00 PM
From: Dennis	Respond to of 25

Hey, cb you started this thread...... Bio-Plexus Reports Increased Revenues and Lower Losses Business Wire - July 20, 1998 13:19 VERNON, Conn.--(BW HealthWire)--July 20, 1998--Bio-Plexus, Inc. (NASDAQ:BPLX), designer, developer, manufacturer, and marketer of safety medical products under the PUNCTUR-GUARD(R) name, today announced at its annual meeting that it has increased revenues and significantly reduced losses in the quarter ended June 30, 1998. Total revenues for the quarter increased to $2,339,000 from $954,000 and net losses were $143,000 or $0.01 per common share, compared to $3,658,000 or $0.46 per common share for the same period a year ago. "The improvements are in large part the result of increased activity on our safety I.V. catheter project, but also reflect our ongoing efforts to get our financial house in order," said Richard Higgins, president and chief executive officer. "These efforts include more cost-effective manufacturing operations, careful expense management, and a marketing strategy that focuses on the bottom line rather than the top line," Higgins added. "We are also working to support the safety movement, and Tom Sutton, our executive vice president of marketing and administration has been appointed to the OSHA Advisory Committee in California that is considering the possibility of mandating the use of safety needle products. This is an important initiative, and one that Bio-Plexus will continue to support," Higgins added. Bio-Plexus holds U.S. and international patents on safety medical devices marketed under the Punctur-Guard name. These devices are designed to reduce the incidence of accidental needlesticks among healthcare workers. In a Centers for Disease Control study, Punctur-Guard Blood Collection Needles were found to reduce the rate of accidental needlesticks by 76%, the highest rate of any device studied. Accidental needlesticks number more than 950,000 per year in the United States and can result in the transmission of deadly diseases including HIV and Hepatitis B and C.